NCT05575804 - GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

January 1, 2025

Study Completion Date

January 1, 2025

Conditions

Advanced/ Metastatic Her-2 Positive Breast Cancer

Interventions

DRUG

GQ1001+pyrotinib

GQ1001 infusions on day 1 of each 21-day cycle combinate with pyrotinib 320mg orally once daily until disease progression or unacceptable toxicity. I.

DRUG

pyrotinib+capecitabine

pyrotinib 400mg orally once daily in combination with capecitabine 1000mg/m2 twice daily, day1-14, every three weeks until disease progression or unacceptable toxicity.

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

collaborator

GeneQuantum Healthcare (Suzhou) Co., Ltd.

INDUSTRY

lead

Fudan University

OTHER